Clinical Trial: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational

Official Title: Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of TNM Staging System in Nasopharyngeal Carcinoma: A Prospective Multi-institutional Observation Study

Brief Summary:

RATIONALE

  1. In patients with nasopharyngeal carcinoma, there is sometimes a discrepancy between actual clinical outcome and TNM stages because it is an anatomy-based system in which functional factors are not concerned.
  2. Hemoglobin, neutrophil to lymphocyte ratio and platelet count were proved to improve prognosis prediction of TNM staging system in our previous retrospective study.

PURPOSE To validate that the prognostic index based on complete blood count and TNM system had higher prediction efficiency on survival in nasopharyngeal carcinoma than TNM system alone.


Detailed Summary: 500 patients with non-metastatic nasopharyngeal carcinoma will be include and will be divided into 3 groups (Low Risk, Intermediate Risk and High Risk Groups) according to their prognostic index, which is on basis of blood cell count indexes and TNM stage. The 3 groups of patients will undergo a radical radiotherapy or chemoradiotherapy and be followed until death or the end of the study. Comparison on survivals of the 3 groups will be made to validate the accuracy of the prognostic index. And comparison on prediction efficacy between prognostic index and TNM staging system will be made.
Sponsor: Sun Yat-sen University

Current Primary Outcome: 5-year overall survival [ Time Frame: 5 years after diagnosis ]

The period until any event (death, local recurrence or distant metastasis) is detected.


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • 5-year disease-free survival [ Time Frame: 5 years after diagnosis ]
    The period until local recurrence or distant metastasis is detected.
  • 5-year recurrence-free survival [ Time Frame: 5 years after diagnosis ]
    The period until local recurrence is detected.
  • 5-year distant-free survival [ Time Frame: 5 years after diagnosis ]
    The period until distant metastasis is detected.


Original Secondary Outcome: Same as current

Information By: Sun Yat-sen University

Dates:
Date Received: August 5, 2014
Date Started: August 2014
Date Completion: December 2022
Last Updated: April 13, 2016
Last Verified: April 2016